News
AbbVie’s Skyrizi took home the top spot for most pharma brand ad impressions in April 2025, according to data released by ...
AbbVie snagged yet another spot among April’s highest TV ad spenders, as its Vraylar jumped two spots to eighth place with a ...
Pharma giant AbbVie has been taken to task by the FDA for running an ad for one of its migraine drugs, featuring tennis star Serena Williams, which the agency says overstates its efficacy.
AbbVie will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 14, 2025. Management will participate in a fireside chat at 12:00 p.m. Central time. A live audio ...
Royalty Receipts was $788 million in the first quarter of 2025, an increase of 12% compared to $705 million in the first quarter of 2024. The increase was primarily driven by strong growth from the ...
Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12%Net cash provided by operating activities of $596 millionRaised full year 2025 guidance: Portfolio Receipts expected to ...
Drugmakers in the US have been exempted from tariffs but the pills and capsules may soon hit the fan. They are lobbying US president Donald Trump for more time to absorb tariffs and perhaps move their ...
AbbVie Inc. closed 15.13% below its 52-week high of $218.66, which the company reached on March 10th.
Despite conclusive proof of Abbvie sponsoring foreign tours for 30 doctors, violating marketing practices, the National ...
In this article, we will take a look at where AbbVie Inc. (NYSE:ABBV) stands against other top stock recommendations by ChatGPT. After a two-year surge of 53%, the stock market has been taken for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results